细胞免疫治疗原发性肝癌的现状及展望

doi:10.3969/j.issn.1672-5069.2015.06.033

摘要/Abstract

摘要： 原发性肝癌患者病程进展快,多数病人确诊时已难以手术切除,且肝癌对放疗、化疗不敏感,因此其总体治疗效果不理想。目前,在肝癌生物治疗的基础及临床研究中,细胞生物治疗已经显示出了潜在的疗效及良好的发展前景。

Abstract: Many patients with hepatocellular carcinoma （HCC） have no opportunity to undergo surgical treatment when diagnosed and HCC is not sensitive to radiotherapy and chemotherapy. Therefore,the overall curative effect of patients with HCC is far from satisfaction. Currently,in the experimental and clinical research on HCC biotherapy,cellular immunotherapy shows potential effects and great perspective. In this review,we summaried the recent advances in cellular immunotherapy for HCC.

Key words: Hepatocellular carcinoma, Cellular immunity, Biotherapy, Current status

郭玲综述，何静，陈东风审校. 细胞免疫治疗原发性肝癌的现状及展望[J]. 实用肝脏病杂志, 2015, 18(6): 687-690.

Guo Ling， He Jing， Chen Dongfeng.. Current status and prospects of cellular immunotherapy for patients with hepatocellular carcinoma[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(6): 687-690.

参考文献

[1] Buendia MA,Neuveut C. Hepatocellular carcinoma. Cold Spring Harb Perspect Med,2015,5（2）:a021444.
[2] Lafaro KJ,Demirjian AN,Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am,2015,24（1）:1-17.
[3] Bertino G,Demma S,Ardiri A,et al. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int,2014,1（203）：693-708.
[4] Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science,2013,342（6165）:1432-1433.
[5] Su CH,Lin Y,Cai L. Genetic factors,viral infection, other factors and liver cancer:an update on current progress. Asian Pac J Cancer Prev,2013,14（9）:4953-4960.
[6] Greten TF,Wang XW,Korangy F. Current concepts of immune based treatments for patients with HCC:from basic science to novel treatment approaches. Gut,2015,64（5）:842-848.
[7] Vinay DS,Ryan EP,Pawelec G,et al. Immune evasion in cancer:Mechanistic basis and therapeutic strategies. Semin Cancer Biol,2015 （In Press）.
[8] Streba LA,Streba CT,Sandulescu L,et al. Dendritic cells and hepatocellular carcinoma. Rom J Morphol Embryol,2014,55（4）:1287-1293.
[9] Takakura K,Kajihara M,Ito Z,et al. Dendritic-tumor fusion cells in cancer immunotherapy. Discov Med,2015,19（104）:169-174.
[10] Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol,2004,4（12）:941-952.
[11] El Ansary M,Mogawer S,Elhamid SA,et al. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC. J Cancer Res Clin Oncol,2013,139（1）:39-48.
[12] Shimizu K, Kotera Y,Aruga A,et al. Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma. Hum Vaccin Immunother,2014,10（4）:970-976.
[13] Lee JH,Lee JH,Lim YS,et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology,2015（In Press）.
[14] Xie F,Zhang X,Li H,et al. Adoptive immunotherapy in postoperative hepatocellular carcinoma:a systemic review. PLoS One,2012,7（8）:e42879.
[15] Olioso P,Giancola R,Di Riti M,et al. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial.Hematol Oncol,2009,27（3）:130-139.
[16] Yu X,Zhao H,Liu L,et al. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. J Clin Immunol,2014,34（2）:194-203.
[17] Cui J,Wang N,Zhao H,et al. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer,2014,134（2）:342-351.
[18] Huang ZM,Li W,Li S,et al. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J Immunother,2013,36（5）:287-293.
[19] Vivier E. What is natural in natural killer cells? Immunol Lett,2006,107（1）:1-7.
[20] Klingemann HG. Cellular therapy of cancer with natural killer cells-where do we stand?Cytotherapy,2013,15（10）:1185-1194.
[21] Pegram HJ,Haynes NM,Smyth MJ,et al. Characterizing the anti-tumor function of adoptively transferred NK cells in vivo.CancerImmunol Immunother,2010,59（8）:1235-1246.
[22] Sun C,Sun H,Zhang C,et al. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol,2014,2（40）:91-110.
[23] Shabani Z,Bagheri M,Zare-Bidaki M,et al. NK cells in hepatitis B virus infection:a potent target for immunotherapy. Arch Virol, 2014,159（7）:1555-1565.
[24] Jiang W,Zhang C,Tian Z,et al. hIL-15 gene-modified human natural killer cells（NKL-IL15） augments the anti-human hepatocellular carcinoma effect in vivo. Immunobiology,2014,219（7）:547-553.
[25] Kochenderfer JN,Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol,2013,10（5）:267-276.
[26] Ritchie DS,Neeson PJ,Khot A,et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther,2013,21（11）:2122-2129.
[27] Gargett T,Brown MP. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2. Cytotherapy,2015,17（4）:487-495.
[28] Maude SL,Frey N,Shaw PA,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med,2014,371（16）:1507-1517.
[29] Lee DW,Kochenderfer JN,Stetler-Stevenson M,et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults:a phase 1 dose-escalation trial. Lancet,2014,385（9967）:517-528.
[30] Riccione K,Suryadevara CM,Snyder D,et al. Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care. J Vis Exp,2015（96）:397-406.
[31] Gao H,Li K,Tu H,et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res,2014,20（24）:6418-6428.
[32] Li H,Wang C,Yu J,et al. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy,2009,11（8）:1076-1083.
[33] 葛薇,李长虹,张伟,等. 树突状细胞与细胞因子诱导的杀伤细胞共培养增强其体内抗肿瘤活性. 中华血液学杂志,2004,25（5）:277-280.
[34] 何立香,蒋思卿,彭大为. DC-CIK治疗恶性肿瘤的研究进展.医学综述,2013,19（1）:59-62.
[35] Shan CC,Shi LR,Ding MQ,et al. Cytokine-induced killer cells co-cultured with dendritic cells loaded with the protein lysate produced by radiofrequency ablation induce a specific antitumor response. Oncol Lett,2015,9（4）:1549-1556.
[36] Shi SB,Ma TH,Li CH,et al. Effect of maintenance therapy with dendritic cells:cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumor,2012,98（3）:314-319.
[37] 郭伟伟,刘莉,吴德华. DC-CIK细胞免疫治疗联合TACE术治疗原发性肝癌. 南方医科大学学报,2014,34（5）:674-678.